The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshiaki Nakamura
Research Funding - Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Tadamichi Denda
Honoraria - Sawai Pharmaceutical Co
Speakers' Bureau - Sysmex
Research Funding - MSD (Inst); Ono Pharmaceutical (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuo Hamamoto
Consulting or Advisory Role - Chugai Pharma; Dainippon Sumitomo Pharma
Research Funding - Bristol-Myers Squibb Japan; Lilly Japan; MSD Oncology; Ono Pharmaceutical
 
Hiroki Hara
No Relationships to Disclose
 
Taito Esaki
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Amgen Astellas BioPharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); IQVIA (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Quintiles (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - LSK BioPharma; Sumitomo Group; Takeda
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma; Daiichi Sankyo (Inst); Lilly Japan (Inst); Sanofi; Taiho Pharmaceutical; Takeda (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Toshikazu Moriwaki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Eisai (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Izumi Miki
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)